Literature DB >> 10971202

Pharmacogenetics of beta-1- and beta-2-adrenergic receptors.

S B Liggett1.   

Abstract

beta(1)- and beta(2)-adrenergic receptors are G protein-coupled receptors expressed throughout the body and serve as receptors for the catecholamines epinephrine and norepinephrine. They are targets for therapeutive agonists and/or antagonists in treatment of heart failure and asthma. Nonsynonymous coding and promoter polymorphisms of both receptors have been identified in the general population. These have been mimicked in transfected cell systems and transgenic mice, and show altered expression, ligand binding, coupling, or regulation phenotypes. Clinical studies to date have revealed that some of these polymorphisms have a significant disease modifying effect or alter the response to treatment. These are some of the first G protein coupled receptor polymorphisms to undergo extensive in vitro study and clinical validation; there are likely to be polymorphisms of other receptors of the superfamily that will have clinical relevance as well. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971202     DOI: 10.1159/000028397

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  22 in total

Review 1.  Genetic polymorphisms of adrenergic receptors.

Authors:  E M Garland; I Biaggioni
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

Review 2.  Asthma from a pharmacogenomic point of view.

Authors:  C Szalai; I Ungvári; L Pelyhe; G Tölgyesi; A Falus
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

3.  The Gordon Wilson Lecture: neurohormonal signaling pathways that link cardiac growth and death.

Authors:  Gerald W Dorn
Journal:  Trans Am Clin Climatol Assoc       Date:  2007

Review 4.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

5.  The Gln27Glu polymorphism in β2-adrenergic receptor gene is linked to hypertriglyceridemia, hyperinsulinemia and hyperleptinemia in Saudis.

Authors:  Maha H Daghestani; Arjumand Warsy; Mazin H Daghestani; Ali N Al-odaib; Abdelmoneim Eldali; Nadia A Al-Eisa; Sabah Al-zhrani
Journal:  Lipids Health Dis       Date:  2010-08-25       Impact factor: 3.876

6.  Immobilization of tyrosinase on Fe3o4@Au core-shell nanoparticles as bio-probe for detection of dopamine, phenol and catechol.

Authors:  Elham Arkan; Changiz Karami; Ronak Rafipur
Journal:  J Biol Inorg Chem       Date:  2019-07-29       Impact factor: 3.358

7.  Nuclear factor kappa B and matrix metalloproteinase induced receptor cleavage in the spontaneously hypertensive rat.

Authors:  Kwan-I Sharon Wu; Geert W Schmid-Schönbein
Journal:  Hypertension       Date:  2011-01-10       Impact factor: 10.190

Review 8.  The functional significance of genetic variation within the beta-adrenoceptor.

Authors:  A J Sandilands; K M O'Shaughnessy
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

Review 9.  Pharmacogenetics of the beta 2-adrenergic receptor gene.

Authors:  Victor E Ortega; Gregory A Hawkins; Stephen P Peters; Eugene R Bleecker
Journal:  Immunol Allergy Clin North Am       Date:  2007-11       Impact factor: 3.479

Review 10.  Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing.

Authors:  Preeti Gupta; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.